Coherus Oncology, Inc. reports commercial-stage oncology developments centered on LOQTORZI® (toripalimab-tpzi), an approved next-generation PD-1 inhibitor for recurrent or metastatic nasopharyngeal carcinoma. Company updates also cover its antibody immunotherapy pipeline, including tagmokitug, an anti-CCR8 cytolytic antibody, and casdozokitug, an IL-27 antagonistic antibody, across solid-tumor programs such as liver, prostate, head and neck, colorectal, gastric and esophageal cancers.
Recurring news includes financial results, LOQTORZI revenue commentary, clinical-development updates, strategic partnerships, investor-conference presentations, public common-stock offerings, debt reduction and other capital-structure actions tied to the company's transition from biosimilars to innovative oncology.
Coherus Oncology (Nasdaq: CHRS) announced on Nov 6, 2025 that Arvind Sood has joined as Chief Strategy and Corporate Affairs Officer, reporting to Denny Lanfear, Chairman and CEO. His remit includes corporate development, investor relations and government affairs. Management said Sood will help clarify Coherus Oncology's value proposition to investors and partners as the company advances commercialization of LOQTORZI® in nasopharyngeal carcinoma and develops pipeline programs: CCR8-targeting antibody CHS-114 (head & neck, gastric, esophageal, colorectal) and IL-27 antagonist casdozokitug (liver, lung). Sood brings over 20 years of senior biopharma experience including roles at Amgen, Innate Pharma, Curogen and Aventis/Sanofi, and holds an MBA and BBA.
Coherus Oncology (Nasdaq: CHRS) will release its third quarter 2025 financial results after market close on Thursday, November 6, 2025. The company will host a conference call and webcast starting at 5:00 p.m. Eastern Time on November 6, 2025 to discuss results and provide a business update.
Investors must pre-register for dial-in details and a PIN; a live webcast and an archived replay will be available on the company’s Investors website at https://investors.coherus.com. The press release and related materials will be posted on the same site before the call begins.
Coherus Oncology (NASDAQ: CHRS) will webcast presentations at three investor conferences in Nov–Dec 2025: the UBS Global Healthcare Conference in Palm Beach Gardens on Nov 10, 2025 at 1:15 PM ET, the Jefferies Global Healthcare Conference in London on Nov 18, 2025 at 10:30 AM GMT, and the Baird Biotech Discovery Series virtual event on Dec 17, 2025 at 1:30 PM ET.
Webcasts and 30-day replays will be available on the company’s Investor Events page at https://investors.coherus.com/events-presentations. One-on-one meeting requests should be coordinated through your bank representative. The company uses its investor website to disclose material non-public information and comply with Regulation FD.
Coherus Oncology (NASDAQ: CHRS) will present a poster at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), Nov 5-9, 2025, in National Harbor, Maryland. Abstract #640 reports that CHS-114, an anti-CCR8 cytolytic monoclonal antibody, “demonstrates selective intratumoral Treg depletion and favorable immune remodeling” in participants with advanced solid tumors. The poster presentation is scheduled for Saturday, November 8, 2025 at Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center.
Additionally, CHS-114 will be featured in SITC’s webinar series "Targets for Cancer IO: A Deep Dive" on October 22, 2025, 12:00–2:00 PM ET, covering CCR8 biology and clinical results, with Coherus faculty Rosh Dias, MD and Varun Kapoor, PhD.
Coherus Oncology (NASDAQ:CHRS) announced its participation in three upcoming investor conferences in September and October 2025. The company will present at the Baird 2025 Global Healthcare Conference on September 9, the H.C. Wainwright Global Investment Conference on September 10, and the UBS Virtual Oncology Day on October 1, 2025.
All presentations will be accessible through webcast links on the company's investor relations website, with replays available for 30 days. Investors interested in one-on-one meetings with management should contact their respective bank representatives.
Coherus Oncology (NASDAQ:CHRS) reported Q2 2025 financial results, highlighting $10.0 million in LOQTORZI net revenue, a 36% increase from Q1 2025. The company ended Q2 with $238 million in cash and completed the UDENYCA divestiture for $483.4 million, with potential milestone payments of up to $75 million.
Key pipeline developments include progress on CHS-114, a cytolytic CCR8 antibody, and casdozokitug, a first-in-class IL-27 antagonist, with data readouts expected in 1H 2026. The company reported a Q2 net loss from continuing operations of $44.9 million ($0.39 per share), while net income from discontinued operations was $342.6 million ($2.95 per share), primarily due to the UDENYCA divestiture gain.
Coherus Oncology (Nasdaq: CHRS) has scheduled its second quarter 2025 financial results release for August 7, 2025, after market close. The company will host a conference call and webcast at 5:00 p.m. EDT on the same day to discuss the results and provide a business update.
Investors can access the conference call through toll-free (800-715-9871) or international (646-307-1963) dial-in numbers using Conference ID 8712736. A live webcast and archived replay will be available on the company's investor relations website.
Coherus BioSciences (NASDAQ: CHRS) has announced a clinical collaboration with STORM Therapeutics to evaluate the combination of STC-15 (a METTL3 inhibitor) with LOQTORZI (toripalimab-tpzi), their next-generation PD-1 inhibitor. The first patient has been dosed in a Phase 1b/2 study targeting multiple cancer types including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, and endometrial cancer.
The study will enroll up to 188 patients in the United States, with Phase 1b focusing on safety and efficacy of the combination, followed by Phase 2 expansion cohorts. Under the agreement, Coherus will supply LOQTORZI while STORM will sponsor the trial, with both companies retaining commercial rights to their respective compounds.